
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
VJHemOnc Podcast
00:00
Introduction
The speakers discuss the poor prognosis of T-cell lymphoma, highlighting the importance of real world data and a prospective study with over 10 years of follow-up. They emphasize the need to consider relapse rates in treatment decisions.
Play episode from 00:00
Transcript


